Nyxoah (NYXH) to Release Quarterly Earnings on Tuesday

Nyxoah (NASDAQ:NYXH) is expected to be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $1.64 million for the quarter.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). The firm had revenue of $1.35 million during the quarter, compared to analysts’ expectations of $2.02 million. Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. On average, analysts expect Nyxoah to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nyxoah Price Performance

NASDAQ:NYXH traded down $0.02 during mid-day trading on Tuesday, hitting $6.47. 76,349 shares of the stock traded hands, compared to its average volume of 68,811. The business’s 50-day moving average price is $7.89 and its 200 day moving average price is $8.81. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. The company has a market cap of $220.33 million, a PE ratio of -3.43 and a beta of 1.56. Nyxoah has a 12-month low of $5.55 and a 12-month high of $12.21.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on NYXH shares. Stifel Nicolaus decreased their price target on shares of Nyxoah from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, April 21st. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Nyxoah in a research note on Tuesday, April 8th.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.